Sihuan Pharmaceutical (00460.HK) makes a strategic investment in Hanteng Biotech, enhancing its layout across the entire regenerative medical aesthetics industry chain.

Zhitong Finance APP News, Sihuan Pharmaceutical (00460.HK) announced that recently, Meiyan Space Biotechnology (Jilin) Co., Ltd. (Meiyan Space), a subsidiary of the Group, has completed a strategic equity investment in Guangzhou Hanteng Biotechnology Co., Ltd. (Hanteng Biotech). At the same time, the two parties plan to carry out joint commercialization cooperation around the commercial sales of Hanteng Biotech's full-length triple-helix recombinant human collagen raw material (the raw material). Meiyan Space will develop a series of collagen medical aesthetics formulation products based on the raw material, improving the Group's regenerative medical aesthetics business layout.